Brokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) PT at $144.25

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been given an average rating of “Moderate Buy” by the ten ratings firms that are presently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $144.25.

TMDX has been the subject of several recent analyst reports. Canaccord Genuity Group raised their target price on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Zacks Research cut TransMedics Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Needham & Company LLC lifted their target price on TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Piper Sandler restated an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of TransMedics Group in a report on Wednesday, October 8th.

Insider Transactions at TransMedics Group

In related news, insider Anil P. Ranganath sold 3,000 shares of TransMedics Group stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total transaction of $435,660.00. Following the completion of the sale, the insider owned 13,955 shares of the company’s stock, valued at approximately $2,026,545.10. The trade was a 17.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director David Weill sold 5,000 shares of the stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total transaction of $693,200.00. Following the completion of the transaction, the director directly owned 12,134 shares in the company, valued at approximately $1,682,257.76. This represents a 29.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 8,920 shares of company stock worth $1,257,310. 7.00% of the stock is owned by insiders.

Institutional Trading of TransMedics Group

Hedge funds have recently added to or reduced their stakes in the company. Whittier Trust Co. of Nevada Inc. grew its holdings in TransMedics Group by 981.0% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after buying an additional 206 shares in the last quarter. Salomon & Ludwin LLC bought a new stake in shares of TransMedics Group in the third quarter valued at about $28,000. Harvest Fund Management Co. Ltd acquired a new position in shares of TransMedics Group in the third quarter valued at about $29,000. Optiver Holding B.V. increased its position in TransMedics Group by 248.1% during the third quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after acquiring an additional 191 shares during the period. Finally, Allworth Financial LP increased its position in TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Price Performance

Shares of TMDX opened at $133.98 on Wednesday. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43. The company’s fifty day simple moving average is $134.30 and its 200 day simple moving average is $123.60. TransMedics Group has a 1-year low of $62.07 and a 1-year high of $156.00. The company has a market cap of $4.58 billion, a price-to-earnings ratio of 54.24 and a beta of 2.03.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The firm had revenue of $143.82 million during the quarter, compared to analysts’ expectations of $145.33 million. The company’s revenue for the quarter was up 32.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.12 earnings per share. On average, research analysts forecast that TransMedics Group will post 1 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.